Suppr超能文献

终末期肾病且长期血液透析伴难治性高血压患者的肾脏去神经支配术。

Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis.

机构信息

Department of Interventional Cardiology.

ESH Excellence Hypertension Center, Verano Brianza.

出版信息

J Hypertens. 2020 May;38(5):936-942. doi: 10.1097/HJH.0000000000002358.

Abstract

INTRODUCTION

Recent randomized controlled trials have confirmed the ability of renal denervation to lower blood pressure (BP) in patients, resistant to the BP-lowering effect of multiple antihypertensive drug administration. Evidence is limited, however, in patients with end-stage renal disease (ESRD) and haemodialysis, a condition in which a persistent BP elevation, despite administration of many antihypertensive drugs, is common. Aim of the present study was to test the BP-lowering efficacy of renal denervation in patients with resistant hypertension and ESRD on haemodialysis. BP was measured repeatedly in the office and over the 24 h during 1-year follow-up.

METHODS AND RESULTS

The study was conducted from February 2017 to January 2018 at the Policlinico of Monza, Monza, Italy. We included 24 men and women aged at least 20 years (mean 55 ± 16) who had ESRD, were on long-term haemodialysis and exhibited resistant hypertension, that is, elevated office and ambulatory BP values, despite multidrug antihypertensive treatment (n = 5.4 ± 1). We excluded patients with renal artery stenosis, malignancy, and a probable life expectancy less than 1 year. Twelve patients were included in the renal denervation and 12 in the medical treatment (control) group. All patients underwent office and 24 h ambulatory BP measurements at baseline and at 1, 6 and 12 months during the follow-up. In the renal denervation group, baseline office and 24 h mean SBP were 180 ± 112 and 175 ± 11 mmHg, respectively, the corresponding values in the control group being 181 ± 19 and 181 ± 20 mmHg. Most of the other baseline characteristics were also similar or only slightly different between groups, including the mean number of administered antihypertensive drugs at baseline. SBP showed an early and persistent reduction after renal denervation (office SBP: 165 ± 13; 150 ± 7 and 149 ± 11mmHg; 24 h SBP 163 ± 20, 148 ± 10 and 149 ± 17 mmHg after 1, 6 and 12 months, respectively). The BP-lowering effect was almost always present and statistically significant during both the day and night. DBP changes followed a similar pattern whereas heart rate never showed any significant change. No significant periprocedural complication of renal denervation was seen. The mean number of administered drugs did not show any significant BP change during the study.

CONCLUSION

In ESRD patients under long-term haemodialysis in whom BP was markedly elevated despite administration of many antihypertensive drugs, renal denervation lowered both ambulatory and office BP. The reduction persisted over a 1-year follow-up.

摘要

简介

最近的随机对照试验证实,肾去神经术能够降低对多种降压药物治疗反应不佳的患者的血压(BP)。然而,在终末期肾病(ESRD)和血液透析患者中,证据有限,尽管给予了多种降压药物,血压仍持续升高。本研究旨在测试肾去神经术在接受血液透析的难治性高血压和 ESRD 患者中的降压疗效。在 1 年的随访期间,通过办公室和 24 小时反复测量血压。

方法和结果

该研究于 2017 年 2 月至 2018 年 1 月在意大利蒙扎的 Policlinico 进行。我们纳入了 24 名年龄至少 20 岁的男性和女性(平均 55±16 岁),他们患有 ESRD,长期接受血液透析,并表现出难治性高血压,即办公室和动态血压值升高,尽管接受了多种降压药物治疗(n=5.4±1)。我们排除了肾动脉狭窄、恶性肿瘤和预期寿命可能小于 1 年的患者。12 名患者被纳入肾去神经术组,12 名患者被纳入药物治疗(对照组)。所有患者在基线时和随访期间的 1、6 和 12 个月时进行办公室和 24 小时动态血压测量。在肾去神经术组中,基线办公室和 24 小时平均收缩压分别为 180±112mmHg 和 175±11mmHg,对照组相应值分别为 181±19mmHg 和 181±20mmHg。两组之间的大多数其他基线特征也相似或仅略有不同,包括基线时给予的平均降压药物数量。肾去神经术后 SBP 早期且持续降低(办公室 SBP:165±13mmHg;150±7mmHg 和 149±11mmHg;24 小时 SBP:163±20mmHg、148±10mmHg 和 149±17mmHg,分别在 1、6 和 12 个月后)。BP 降低的效果在白天和夜间几乎一直存在且具有统计学意义。DBP 变化呈现类似模式,而心率从未出现任何显著变化。肾去神经术没有出现明显的围手术期并发症。在研究期间,给予的药物数量平均值没有显示出任何显著的 BP 变化。

结论

在长期血液透析的 ESRD 患者中,即使给予了多种降压药物,血压仍明显升高,肾去神经术可降低动态和办公室血压。这种降低在 1 年的随访中持续存在。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验